Sponsor or institution
Clinical trials and research at Nuclear Imaging Institute
As of November 12, 2026, Find a Trial lists 5 clinical trials run by Nuclear Imaging Institute that are recruiting, in United States. By phase: Phase 2 (5). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Ultralow-dose PET imaging of somatostatin receptor 2 (SSTR2) uptake | Phase 2 | Englewood, New Jersey | Recruiting | Dec 16, 2025 |
| Ultralow-dose PET scan to detect bone activity with 18F‑NaF | Phase 2 | Englewood, New Jersey and 1 other locations | Recruiting | Dec 16, 2025 |
| Ultralow-dose amyloid PET with 18F‑Florbetapir or 18F‑Flutemetamol | Phase 2 | Englewood, New Jersey | Recruiting | Jun 10, 2025 |
| Ultralow-dose 18F-FDG PET imaging with a high-sensitivity scanner | Phase 2 | Englewood, New Jersey | Recruiting | May 4, 2025 |
| Ultralow-dose PET imaging for PSMA expression in prostate cancer | Phase 2 | Englewood, New Jersey | Recruiting | Apr 1, 2025 |
All recruiting trials (5)
-
Ultralow-dose PET imaging of somatostatin receptor 2 (SSTR2) uptake
This study will test whether an ultralow-dose 68Ga-Dotatate PET scan on a high-sensitivity scanner can detect SSTR2 uptake in adults with and without neuroendocrine tumors.
-
Ultralow-dose PET scan to detect bone activity with 18F‑NaF
This trial tests whether a new high-sensitivity PET scan using a tiny amount of 18F‑sodium fluoride can produce clear bone images in adults with or without bone disease while cutting radiation exposure by 10–100 times.
-
Ultralow-dose amyloid PET with 18F‑Florbetapir or 18F‑Flutemetamol
This trial will try using a very small amount of an amyloid PET tracer with a high-sensitivity PET scanner to see if clear brain images can be made for people with Alzheimer’s, mild cognitive impairment, other dementias, and healthy volunteers.
-
Ultralow-dose 18F-FDG PET imaging with a high-sensitivity scanner
This will test whether an ultralow-dose 18F-FDG PET scan using a high-sensitivity scanner can detect and monitor cancer in people with and without cancer.
-
Ultralow-dose PET imaging for PSMA expression in prostate cancer
This test will try to see if an ultralow-dose PET scan using 18F-DCFPyL can detect PSMA in people with and without prostate cancer while cutting radiation exposure by 10- to 100-fold.
Quick answers
How many clinical trials run by Nuclear Imaging Institute are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in United States. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 5. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.